Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting.
Rimel BJ, Chase DM, Perhanidis J, Ghazarian AA, Du EX, Wang T, Song J, Golembesky AK, Hurteau JA, Kalilani L, Salani R, Monk BJ. Rimel BJ, et al. Among authors: du ex. Gynecol Oncol Rep. 2024 Feb 7;51:101332. doi: 10.1016/j.gore.2024.101332. eCollection 2024 Feb. Gynecol Oncol Rep. 2024. PMID: 38362364 Free PMC article.
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN. Weber JS, et al. Among authors: du ex. Cancer Immunol Immunother. 2023 Apr;72(4):945-954. doi: 10.1007/s00262-022-03302-5. Epub 2022 Oct 5. Cancer Immunol Immunother. 2023. PMID: 36197494 Free PMC article. Clinical Trial.
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN. Weber JS, et al. Among authors: du ex. Cancer Immunol Immunother. 2023 Apr;72(4):955. doi: 10.1007/s00262-022-03351-w. Cancer Immunol Immunother. 2023. PMID: 36538061 Free PMC article. No abstract available.
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
McGregor B, Geynisman DM, Burotto M, Suárez C, Bourlon MT, Barata PC, Gulati S, Huo S, Ejzykowicz F, Blum SI, Del Tejo V, Hamilton M, May JR, Du EX, Wu A, Kral P, Ivanescu C, Chin A, Betts KA, Lee CH, Choueiri TK, Cella D, Porta C. McGregor B, et al. Among authors: du ex. Eur Urol Oncol. 2023 Jun;6(3):339-348. doi: 10.1016/j.euo.2023.01.012. Epub 2023 Feb 25. Eur Urol Oncol. 2023. PMID: 36842942 Free article.
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
Moser JC, Bhatia S, Amin A, Pavlick AC, Betts KA, Du EX, Poretta T, Shelley K, Srinivasan S, Sakkal LA, Palaia J, Lobo M, Pe Benito M, Linton JA, Chen Y, Xu C, Yin L, Sundar M, Weber J. Moser JC, et al. Among authors: du ex. Cancer Immunol Immunother. 2024 May 7;73(7):116. doi: 10.1007/s00262-024-03697-3. Cancer Immunol Immunother. 2024. PMID: 38713408 Free PMC article. Clinical Trial.
32 results